COTA’s Miruna Sasu: I left pharma to “turn the spigot on” in the real-world data industry

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Miruna Sasu spent more than 20 years as a digital health and innovation expert at life sciences companies—then came a realization:

“You can do all kinds of really cool technology things, but if you don’t have data, you can’t apply the technology; right?” Sasu said to The Cancer Letter. “Now that pharma companies can receive it and put it to good use, we want to turn the spigot on.”

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Matthew Bin Han Ong
Associate Editor
Table of Contents


Flatiron Health and FDA’s Oncology Center of Excellence renewed their collaboration to jointly develop and implement specific research projects to advance the use of real-world data and explore the potential strengths and limitations of using real-world evidence for regulatory purposes. The partnership will specifically evaluate RWD study designs and analytic methods through the collaborative development of priority, clinically meaningful research questions regarding care, treatment, and outcomes of patients with cancer.
Matthew Bin Han Ong
Associate Editor